These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10812950)

  • 1. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
    Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
    Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of muscarinic agonists in the treatment of Alzheimer's disease.
    Messer WS
    J Mol Neurosci; 2002; 19(1-2):187-93. PubMed ID: 12212779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
    Messer WS; Abuh YF; Liu Y; Periyasamy S; Ngur DO; Edgar MA; El-Assadi AA; Sbeih S; Dunbar PG; Roknich S; Rho T; Fang Z; Ojo B; Zhang H; Huzl JJ; Nagy PI
    J Med Chem; 1997 Apr; 40(8):1230-46. PubMed ID: 9111297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists.
    Rajeswaran WG; Cao Y; Huang XP; Wroblewski ME; Colclough T; Lee S; Liu F; Nagy PI; Ellis J; Levine BA; Nocka KH; Messer WS
    J Med Chem; 2001 Dec; 44(26):4563-76. PubMed ID: 11741475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
    Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
    Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
    Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
    Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
    Alt A; Pendri A; Bertekap RL; Li G; Benitex Y; Nophsker M; Rockwell KL; Burford NT; Sum CS; Chen J; Herbst JJ; Ferrante M; Hendricson A; Cvijic ME; Westphal RS; O'Connell J; Banks M; Zhang L; Gentles RG; Jenkins S; Loy J; Macor JE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):293-304. PubMed ID: 26582730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the binding and activity at muscarinic receptor subtypes and chimeras.
    Tejada FR; Nagy PI; Xu M; Wu C; Katz T; Dorsey J; Rieman M; Lawlor E; Warrier M; Messer WS
    J Med Chem; 2006 Dec; 49(25):7518-31. PubMed ID: 17149881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
    Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
    Fisher A; Heldman E; Gurwitz D; Haring R; Karton Y; Meshulam H; Pittel Z; Marciano D; Brandeis R; Sadot E; Barg Y; Pinkas-Kramarski R; Vogel Z; Ginzburg I; Treves TA; Verchovsky R; Klimowsky S; Korczyn AD
    Ann N Y Acad Sci; 1996 Jan; 777():189-96. PubMed ID: 8624083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance and prospects for design of selective muscarinic agonists.
    Jakubík J; Michal P; Machová E; Dolezal V
    Physiol Res; 2008; 57 Suppl 3():S39-S47. PubMed ID: 18481916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions.
    McDonald MP; Willard LB; Wenk GL; Crawley JN
    J Neurosci; 1998 Jul; 18(13):5078-85. PubMed ID: 9634573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders.
    Cao Y; Zhang M; Wu C; Lee S; Wroblewski ME; Whipple T; Nagy PI; Takács-Novák K; Balázs A; Torös S; Messer WS
    J Med Chem; 2003 Sep; 46(20):4273-86. PubMed ID: 13678406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors.
    Lazareno S; Popham A; Birdsall NJ
    J Mol Neurosci; 2002; 19(1-2):123-7. PubMed ID: 12212769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
    Dunbar PG; Durant GJ; Rho T; Ojo B; Huzl JJ; Smith DA; el-Assadi AA; Sbeih S; Ngur DO; Periyasamy S
    J Med Chem; 1994 Aug; 37(17):2774-82. PubMed ID: 8064804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of threonine 192 and asparagine 382 in agonist and antagonist interactions with M1 muscarinic receptors.
    Huang XP; Nagy PI; Williams FE; Peseckis SM; Messer WS
    Br J Pharmacol; 1999 Feb; 126(3):735-45. PubMed ID: 10188986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M
    Russell JK; Ingram SM; Teal LB; Lindsley CW; Jones CK
    ACS Chem Neurosci; 2023 Feb; 14(3):435-457. PubMed ID: 36655909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation.
    Rosas-Ballina M; Valdés-Ferrer SI; Dancho ME; Ochani M; Katz D; Cheng KF; Olofsson PS; Chavan SS; Al-Abed Y; Tracey KJ; Pavlov VA
    Brain Behav Immun; 2015 Feb; 44():19-27. PubMed ID: 25063706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of 18F-labeled muscarinic agonist with M2 selectivity.
    Kiesewetter DO; Lee J; Lang L; Park SG; Paik CH; Eckelman WC
    J Med Chem; 1995 Jan; 38(1):5-8. PubMed ID: 7837240
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.